Novocure (NVCR) Misses Q1 EPS by 10c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
NovoCure Ltd. (NVCR) PT Raised to $31 at Deutsche Bank
April 27, 2018 7:46 AM EDTDeutsche Bank raised its price target on NovoCure Ltd. (NASDAQ: NVCR) to $31.00 (from $29.00) while maintaining a Buy rating.
Analyst Gregg Gilbert commented, "NVCR reported strong patient uptake in GBM globally, with US contributing a majority of the increase in patient numbers... More



